Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2018 Aug 15:4:21.
doi: 10.1038/s41523-018-0072-8. eCollection 2018.

Is there a role for immunotherapy in HER2-positive breast cancer?

Esther Holgado  1   2 , Jose Perez-Garcia  3   4 , Maria Gion  1 , Javier Cortes  1   2   5
Affiliations
Review

Is there a role for immunotherapy in HER2-positive breast cancer?

Esther Holgado et al. NPJ Breast Cancer. .

Abstract

Although the prognosis and prediction of therapeutic benefit for breast cancer patients overexpressing the human epidermal growth factor receptor 2 (HER2) have dramatically changed with the administration of anti-HER2-targeted therapies, HER2-positive metastatic breast cancer is still an incurable disease. Thus, new and better therapeutic options are urgently needed. Among them, are the agents stemming from the field of immunology that have been the focus of impressive scientific progress and new therapeutic opportunities seem to emerge "every day" in a variety of tumor types.

PubMed Disclaimer

Conflict of interest statement

J.C. received honoraria from Roche, Novartis, Eisai, Celgene, Pfizer. Consulting/advisor: Roche, Celgene, Aztrazeneca, Cellestia Biotech, Biothera, Merus. The remaining authors declare no competing interests.

References

    1. Alexandrov LB, et al. Signatures of mutational processes in human cancer. Nature. 2013;500:415–421. doi: 10.1038/nature12477. - DOI - PMC - PubMed
    1. Vogelstein B, et al. Cancer genome landscapes. Science. 2013;339:1546–1558. doi: 10.1126/science.1235122. - DOI - PMC - PubMed
    1. Luen S, Virassamy B, Savas P, Salgado R, Loi S. The genomic landscape of breast cancer and its interaction with host immunity. Breast. 2016;29:241–250. doi: 10.1016/j.breast.2016.07.015. - DOI - PubMed
    1. Denkert C, et al. Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer. J. Clin. Oncol. 2010;28:105–113. doi: 10.1200/JCO.2009.23.7370. - DOI - PubMed
    1. Loi S. Tumor-infiltrating lymphocytes, breast cancer subtypes and therapeutic efficacy. Oncoimmunology. 2013;2:e24720. doi: 10.4161/onci.24720. - DOI - PMC - PubMed